The Monetary Authority of Singapore’s recent policy and regulatory changes paving the way for new issuers to dual-list on NASDAQ and the Singapore Exchange mark a meaningful step forward for the Singapore capital markets. The initiative directly addresses a long-standing challenge: high-growth Asian companies — particularly in the high-tech and bio-pharmaceutical sectors — have traditionally favoured Hong Kong over Singapore when seeking access to public equity for expansion.
From recent interactions with listing aspirants located across Asia, the appeal of a “two-in-one” platform is clear. The ability for an SGX listing to be paired concurrently with NASDAQ access offers IPO candidates dual liquidity, broader investor reach, and a credible North American footprint without requiring a separate listing exercise. For founders and boards weighing exchange selection, that combination meaningfully changes the calculus.
For Singapore, the policy is more than a competitive response. It positions the SGX as a viable home base for the next generation of Asian growth issuers, while leveraging NASDAQ’s depth and global brand to retain capital and corporate activity that might otherwise route through other jurisdictions. The bio-pharmaceutical and deep-tech segments — where Hong Kong’s Chapter 18A and 18C frameworks have set strong precedents — are likely to see the most immediate interest.
I shared these views with Mr Benjamin Cher of the Singapore Business Times in the Top Stories report published on 1 May 2026. The full LinkedIn note is here.